Study of HAIC added on chemotherapy in patients with with unresectable advanced Hepatocellular Carcinoma

Efficacy and safety of Combination therapy of Hepatic Arterial Infusion Chemotherapy and Atezolizumab with Bevacizumab for patients with unresectable advanced Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061210065

Enrollment

Registered

2021-12-17

Start date

2022-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced Hepatocellular Carcinoma Hepatocellular Carcinoma

Interventions

Make a comparison between two groups of Unresectable advanced Hepatocellular Carcinoma. One group is given the chemotherapy with Atezolizumab plus Bevacizumab. Other is given the HAIC within 4 weeks a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 20 age old over 2 Regardless of gender 3 Less than 1 of performance status 4 Patients who diagnosed with unresectable advanced Hepatocellular Carcinoma 5 Patients who have no treatment history of HAIC with Cisplatin 6 Patients who are getting treatment with Atezolizumab plus Bevacizumab 7 Measurable tumors in the liver 8 Patienst who have been fully informed consent

Exclusion criteria

Exclusion criteria: 1 Patients with Child-Pugh score of 8 points or more 2 Allergy for contrast media 3 Less than 30 mL/min of eGFR 4 Allergy for Cisplatin 5 Allergy for Atezolizumab 6 Allergy for Bevacizumab 7 History of Hemoptysis 8 History of autoimmune disease 9 Interstitial pneumonia 10 Intraperitoneal inflamation or wounded 11 Brain metastasis 12 Congenital hemorrhagic disease 13 Severe Hart failure 14 Being pregnant or possibly pregnant 15 Patients who judged as inappropriate candidate by the chief medical examine

Design outcomes

Primary

Measure	Time frame
Response Rate(mRECIST)	—

Secondary

Measure	Time frame
1 Response Rate(RECIST ver1.1) 2 Progression-Free Survival 3 Disease Control Rate 4 Overall Survival 5 Response Rate, Progression-Free Survival, Disease Control Rate, Overall Survival by past treatment 6 Transition rate to curative treatment 7 Adverse Event	—

Contacts

Public ContactYasuto Takeuchi

Okayama University Hospital

yasuto19800125@okayama-u.ac.jp+81-86-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026